Dr. Villemagne is a physician scientist in full-time research specialising in the development of molecular biomarkers for discovery, diagnosis, prognosis and clinical trials in neurodegenerative diseases.

He has determined the natural history of amyloid accumulation in the human brain showing it is a long and protracted process that last decades, affording a wide window for disease-specific therapeutic interventions. He has also pioneered the field of selective tau imaging, and now is expanding to the assessment of reactive astrogliosis. Dr. Villemagne has used both amyloid and tau imaging to assess their respective and combined effect on cognition and brain volumetrics.

He has extensively worked with national and international collaborators through several NIH, NHMRC and DOD funded grants and publications. More than 30-year experience in molecular imaging with PET in neurological and psychiatric conditions.

• 2020 – Present Professor, Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA
• 2020 – Present Co-Director, Molecular Biomarkers in Psychiatry, Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA
• 2020 – Present Professor, School of Medical and Health Sciences, Edith Cowan University, Perth, Australia
• 2010 – Present Associate Professor, Department of Medicine, Austin Health, The University of Melbourne, Melbourne, Australia